Press release
September 12, 2011
Therapy Cells Inc.
584 Main Street
Saint Helena, CA 94574
Patrick Casey BVSc, PhD, MRCVS
President and founding scientist
Leading Bio-Tech Firm Moves to US
Today leading New Zealand biotechnology company Therapy Cell Ltd announced it was moving to the United States through its merger with Therapy Cells Inc (formerly DIII OTC Market). This exciting Bio Tech/Med tech Company holds the exclusive technology that allows adult cells from an individual's specific tissue (e.g. Achilles tendon) to grow again enacting repair and regeneration of that tissue.
Renowned scientist Dr. Patrick (Paddy) Casey, who shares his time between the University of Auckland and labs at UC Davis, has been appointed President and Chief Scientific Officer of Therapy Cells Inc. Dr. Casey said, “To our knowledge, we are the only company in the World that has this proven technology, which is in a strong patent position and effectively by-passes the need for Stem Cell Treatment. We are very excited about entering the US market and pursuing FDA approval”.
This technology has been appraised currently at an initial valuation of $30 million US dollars. Upon FDA approval for clinical use of this technology in humans will likely increase this factor by at least 10 times as much.
Therapy Cells, which is headed by Dr Casey, has very strong links to the San Francisco bay area. Therapy Cells has collaborated with and has laboratories at University of California, Davis. “The natural synergy and roll out is obvious” said President/CS Dr Paddy Casey.
After explaining that the safety and efficacy work of this transformational technology has been completed in the FDA approved model species for athletic injury (the horse is the recognized species for athletic injury in this case), Dr Casey says that “We are anticipating FDA approval of our process within 12 to 18 months maximum”
The company can be reached at , or www.therapycells.com or Facebook page Therapy Cells.
These are exciting times indeed!
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.The words or phrases "would be," "would allow," "intends to," "will likely result," "are expected to," "will continue," "anticipate," "expect," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "considers," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These include the Company's historic lack of profitability, end user customer acceptance and actual demand, which may differ significantly from expectations, the need for the Company to manage its growth, the need to raise funds for operations and other risks within the regulation of the industry. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events or circumstances after the date of such statement.